Advertisement

Cancer Immunology, Immunotherapy

, Volume 63, Issue 12, pp 1341–1346 | Cite as

Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

  • Magnus Pedersen
  • Rikke Andersen
  • Peter Nørgaard
  • Søren Jacobsen
  • Peter Thielsen
  • Per thor Straten
  • Inge Marie Svane
Original Article

Abstract

Two patients were treated with immunotherapy for metastatic malignant melanoma (MM) despite suffering from systemic autoimmune disease, i.e., ulcerative colitis (UC) and Behcets disease (BD), respectively. Both patients benefitted from the treatment. The patient with UC achieved partial remission of all measurable parameters after treatment with Ipilimumab, while the patient with BD achieved a complete remission of MM after treatment with Interleukin-2 (IL-2) and Interferon-α (IFN-α). Moreover, no aggravation of symptoms related to the autoimmune diseases was seen during treatment, in contrast, clinical indications of improvement were observed. These two cases illustrate that the presence of autoimmune disease does not necessarily predict increased autoimmune toxicity in connection with immunotherapy. They also raise the question of whether autoimmune disease should continue to be an absolute exclusion criterion for treatment of MM with immunotherapy. Consequently, given the poor prognosis of refractory MM, immunotherapies need to be taken into consideration even in cases of autoimmune comorbidity due to the potential long-term benefit that these therapies offer to MM patients.

Keywords

Metastatic malignant melanoma Immune therapy Systemic autoimmune disease Ipilimumab Interleukin-2 

Abbreviations

anti-CTLA4

mAbAnti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody

BD

Behcets disease

IL-2

Interleukin-2

IFN-α

Interferon-α

MM

Malignant melanoma

UC

Ulcerative colitis

Notes

Conflict of interest

The authors have no conflicts of interests to disclose.

References

  1. 1.
    Wolchok JD, Yang AS, Weber JS (2010) Immune regulatory antibodies: are they the next advance? Cancer J 16:311–317PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550–4557PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB (2013) The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 10:588–598PubMedCrossRefGoogle Scholar
  4. 4.
    Waldmann TA (2006) The biology of Interleukin-2 and Interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6:595–601PubMedCrossRefGoogle Scholar
  5. 5.
    Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5:375–386PubMedCrossRefGoogle Scholar
  6. 6.
    Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM, Espinosa E, Guo J, Hauschild A, Petrella T, Schachter J, Hersey P (2009) Immunotherapy of distant metastatic disease. Ann Oncol 20(Suppl 6):vi41–vi50PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Keilholz U, Scheibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, Richter M, Brado B, Mitrou PS, Hunstein W (1993) Interferon-alpha and Interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer 72:607–614PubMedCrossRefGoogle Scholar
  8. 8.
    Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16:5–24PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R (2010) Development of Ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 37:533–546PubMedCrossRefGoogle Scholar
  10. 10.
    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Schadendorf D, Hauschild A (2014) Melanoma in 2013: Melanoma–the run of success continues. Nat Rev Clin Oncol 11:75–76PubMedCrossRefGoogle Scholar
  12. 12.
    Feakins RM (2013) Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines. J Clin Pathol 66:1005–1026PubMedCrossRefGoogle Scholar
  13. 13.
    Ford AC, Moayyedi P, Hanauer SB (2013) Ulcerative colitis. BMJ 346:f432PubMedCrossRefGoogle Scholar
  14. 14.
    Mat C, Yurdakul S, Sevim A, Ozyazgan Y, Tuzun Y (2013) Behcet’s syndrome: facts and controversies. Clin Dermatol 31:352–361PubMedCrossRefGoogle Scholar
  15. 15.
    Dalvi SR, Yildirim R, Yazici Y (2012) Behcet’s Syndrome. Drugs 72:2223–2241PubMedCrossRefGoogle Scholar
  16. 16.
    Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von MR, Weder P, Wilhelm T, Goppner D, Dummer R, Heinzerling LM (2013) The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the Ipilimumab network. PLoS One 8:e53745PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Slangen RM, van den Eertwegh AJ, van Bodegraven AA, de Boer NK (2013) Diarrhoea in a patient with metastatic melanoma: ipilimumab ileocolitis treated with infliximab. World J Gastrointest Pharmacol Ther 4:80–82PubMedCentralPubMedGoogle Scholar
  18. 18.
    Walker LS, Sansom DM (2011) The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 11:852–863PubMedCrossRefGoogle Scholar
  19. 19.
    Holmen N, Lundgren A, Lundin S, Bergin AM, Rudin A, Sjovall H, Ohman L (2006) Functional CD4 + CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis 12:447–456PubMedCrossRefGoogle Scholar
  20. 20.
    Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, Maio M, Sucker A, Schilling B, Schadendorf D, Buttner P, Garbe C, Pawelec G (2014) Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res 20:1601–1609PubMedCrossRefGoogle Scholar
  21. 21.
    Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caraco C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, Sandomenico F, Petrillo A, Botti G, Fulciniti F, Palmieri G, Queirolo P, Marchetti P, Ferraresi V, Rinaldi G, Pistillo MP, Ciliberto G, Mozzillo N, Ascierto PA (2014) Immunological and biological changes during Ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 63:675–683PubMedCrossRefGoogle Scholar
  22. 22.
    Sugi-Ikai N, Nakazawa M, Nakamura S, Ohno S, Minami M (1998) Increased frequencies of Interleukin-2- and interferon-gamma-producing T cells in patients with active Behcet’s disease. Invest Ophthalmol Vis Sci 39:996–1004PubMedGoogle Scholar
  23. 23.
    Yalcindag FN, Uzun A (2012) Results of interferon alpha-2a therapy in patients with Behcet’s disease. J Ocul Pharmacol Ther 28:439–443PubMedCrossRefGoogle Scholar
  24. 24.
    Shevach EM (2012) Application of IL-2 therapy to target T regulatory cell function. Trends Immunol 33:626–632PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Magnus Pedersen
    • 1
    • 2
  • Rikke Andersen
    • 1
    • 2
  • Peter Nørgaard
    • 3
  • Søren Jacobsen
    • 4
  • Peter Thielsen
    • 5
  • Per thor Straten
    • 1
  • Inge Marie Svane
    • 1
    • 2
  1. 1.Department of Haematology and Oncology, Center for Cancer Immune TherapyHerlev Hospital, University of CopenhagenHerlevDenmark
  2. 2.Department of Oncology, Herlev HospitalUniversity of CopenhagenHerlevDenmark
  3. 3.Department of Pathology, Herlev HospitalUniversity of CopenhagenHerlevDenmark
  4. 4.Department of Infectious Diseases and Rheumatology, RigshospitaletCopenhagen University HospitalCopenhagenDenmark
  5. 5.Department of Gastroenterology, Herlev HospitalUniversity of CopenhagenHerlevDenmark

Personalised recommendations